Menu Search
Equities

Beijing Tong Ren Tang Chinese Medicine Co Ltd

TQR:FRA

Beijing Tong Ren Tang Chinese Medicine Co Ltd

Actions
  • Price (EUR)0.95
  • Today's Change-0.025 / -2.56%
  • Shares traded5.00k
  • 1 Year change-37.09%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Beijing Tong Ren Tang Chinese Medicine Company Limited is a company mainly engaged in the manufacturing and sale of Chinese medicine. Along with subsidiaries, it operates its business through three segments. The Hong Kong segment engages in the sale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments through retail outlets as well as wholesale of Chinese medicine products in Hong Kong. It is also involved in the royalty fee income from overseas entities using the brand of Tong Ren Tang. The Mainland China segment engages in the wholesale of healthcare products in Mainland China and the sole distribution of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd. to customers outside Mainland China. The Overseas segment engages in the retail and wholesale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments in other overseas countries.

  • Revenue in HKD (TTM)1.38bn
  • Net income in HKD494.14m
  • Incorporated2004
  • Employees779.00
  • Location
    Beijing Tong Ren Tang Chinese Medicine Co LtdRoom 1405-1409, Office Tower, Hong KongHKG
  • Phone+852 36575819
  • Fax+852 28817606
  • Websitehttps://cm.tongrentang.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.